SCHEMBL24846895

SCHEMBL24846895

COc1ccc2[nH]c(=O)n(C)c2c1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ CCNT1 O60563 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ ABCB1 P08183 2/20 0.40
▸ STS P08842 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ F13A1 P00488 1/20 0.40
▸ TGM2 P21980 1/20 0.40
▸ TGM1 P22735 1/20 0.40
▸ SMPD3 Q9NY59 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SUV39H2 Q9H5I1 1/20 0.39
▸ PDE4B Q07343 2/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4C Q08493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26447780 0.87 MEN1 (0.42) GPR119ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL25337018 0.86 GPR119 (0.41) GPR119ALDH1A1STSLMNAMAPT
SCHEMBL30180044 0.82 HTR7 (0.37) ALDH1A1BRD4LMNAMAPTKMT2A
SCHEMBL23832667 0.81 MEN1 (0.48) GPR119ALDH1A1STSLMNAMAPT
SCHEMBL29751443 0.80 AAK1 (0.39) GPR119BRD4PDE4BPDE4APDE4C
SCHEMBL24607488 0.80 AAK1 (0.39) GPR119BRD4PDE4BPDE4APDE4C
SCHEMBL22848653 0.80 PARP1 (0.45) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL29502336 0.80 PARP1 (0.45) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL25338892 0.77 KIT (0.46) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL5704790 0.77 PDE4B (0.43) GPR119ALDH1A1CCNT1CDK9ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 GPR119 4141/4885ALDH1A1 2904/4885BRD4 856/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 GPR119 4141/4885ALDH1A1 2904/4885BRD4 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback